Navigating Joint Clinical Assessment (JCA) and the EU HTA Regulation: Early Evidence, Global Strategy, and Dossier Development
Joint Clinical Assessment (JCA) under the EU HTA Regulation (HTAR) is reshaping evidence, strategy, and launch planning in Europe. Earlier evidence expectations, tighter scrutiny of comparators and outcomes, and a single EU-level clinical assessment mean manufacturers now require clearer foresight, stronger evidence alignment and earlier integration with global strategy.
Why JCA Matters for Global and European Strategy
The introduction of JCA has the potential to impact your global market access and health economics and outcomes research (HEOR) strategy more broadly. Manufacturers with the JCA as a potential milestone in their launch need to consider:
- Global evidence planning and study design
- The feasibility of planned endpoints, comparators and populations in EU
- The timing and JCA-readiness of global value/reimbursement dossiers
- Pricing and value demonstration strategies
- Downstream national health technology assessment (HTA) submissions
The pace and expectations of the EU HTA framework now mean gaps that could previously be managed at national level can rapidly become critical at EU level. To succeed, manufacturers need to ensure that clinical evidence, payer expectations, and global value strategy are aligned.
Get in touch with the teamOur JCA services
- Analogue assessment
- Comparator and endpoint feasibility
- Joint Scientific Consultation (JSC) support
- Pricing and launch sequencing
- PICO scenario planning
- EU payer insight and in-country validation
- Evidence synthesis and systematic reviews
- ITCs and NMAs
- JCA-ready global value/reimbursement dossier development
- 100‑day JCA “sprint” enablement
- JCA dossier development
- National HTA adaption and economic modeling
Our approach
Why Partner with Petauri for JCA Strategy and Evidence Planning
Preparing for a JCA is not just a technical exercise; it requires a coordinated strategy that connects global evidence generation, EU expectations, pricing insight, and national access considerations.
At Petauri, we partner with manufacturers to bring clarity, structure, and foresight to this process.
Your JCA partners
Our clients benefit from an interdisciplinary team combining:
- Evidence synthesis and systematic review expertise
- Advanced statistical capability including indirect treatment comparison (ITC)/network meta-analysis (NMA) capability
- Global access and pricing strategy
- Market access and payer insight
- In-country expert validation
- Expert medical writing and dossier development
We work collaboratively, acting as an extension of your internal teams. Our role is to help you identify the right questions early, anticipate likely JCA scenarios, and ensure that your evidence, analyses and narrative can withstand EU-level scrutiny.
Solving your JCA challenges
We can help solve strategic questions such as:
- Are our planned comparators, populations and endpoints the right ones for JCA, or do early assumptions need to be challenged?
- Where are the critical evidence gaps, and how do we address them before timelines become compressed?
- How do we align our evidence generation plan with both global needs and the population, intervention, comparator, outcome (PICO) scenarios most likely under JCA?
- What can we do now to prepare for tight timelines, even if PICOs are not yet finalized?
- How do we ensure coherence between our global value strategy, JCA requirements, and national HTA expectations?
We have extensive experience across the key disease areas currently in scope, including oncology, rare disease, advanced therapy medicinal products (ATMPs), and medical devices.
We bring the crossfunctional alignment that JCA demands, ensuring clinical, HEOR, statistical, pricing, and market access perspectives stay connected throughout planning and delivery.
Meet our expert team
Samantha Gillard
Director, HTA
Simone Critchlow
Director, HEOR
Jodie Worrall
Director, Systematic Review
Shona Lang
Director, Systematic Review
Anthony Hatswell
Chief Scientific Officer
Clare Foy
Director, Global Pricing and Market Access
Sophie Streeton
Associate Director – Global Value
Catherine Beecher
Director – Global Pricing and Market Access
Preparing for Joint Clinical Assessment (JCA): Early Evidence and PICO Planning
Anticipating JCA PICO Scenarios and Feasibility Analysis
Understanding which populations, interventions, comparators, outcomes (PICOs) are likely to be requested, and whether your evidence can meet them, is a core part of JCA preparation.
Early PICO and feasibility analysis helps manufacturers to:
- Identify evidence gaps ahead of tight JCA timelines
- Assess whether planned comparators are feasible under JCA expectations
- Align early assumptions with EU payer expectations
- Determine whether endpoints and populations will withstand EU-level scrutiny
- Analyze early PICO results for evidence feasibility
- Prepare practical analytic pathways for systematic literature review (SLR) updates and ITCs
- Get prepared to meet the pace and expectations of the JCA process
Using Early Scientific Advice (JSC) to Shape Evidence Generation
Joint Scientific Consultation (JSC) is the formal, early advice mechanism provided under the EU HTA Regulation. It enables manufacturers to seek guidance from EU HTA bodies during the planning of clinical studies on the evidence likely to be needed for future JCAs.
JSC is particularly valuable when:
- Comparator choices or endpoint selection may be contested under JCA
- Feasibility analysis indicates uncertainty about whether planned evidence will satisfy EU HTA expectations
- Alignment is needed between regulatory evidence and JCA requirements
- Clinical studies are still at a stage where design adjustments are possible, as JSC can only be requested while studies are being planned
- Manufacturers need early assurance that evidence generation will support both European Medicines Agency (EMA) review and future JCA, as intended by the Regulation
Used strategically, JSC helps strengthen the evidence base you will rely on for JCA and minimizes the risk of needing reactive changes once PICOs are issued.
JCA‑Ready Global Reimbursement Dossiers
Global value and reimbursement dossiers (GVDs/GRDs) should now anticipate JCA needs. This involves:
- Developing timely global dossiers that support adaptation of content for the JCA dossier
- Providing clinical evidence that aligns with likely PICOs, while ensuring dossier usability and ease of navigation
- Building a clear, differentiating value narrative that can be leveraged for the JCA dossier and for national HTA submissions
- Balancing JCA requirements with the needs of markets outside Europe, to ensure global dossiers remain useful for broad stakeholders
Getting this right will reduce duplication of effort, maintain consistent strategic messaging across markets, and streamline downstream HTA submissions.
Indirect Treatment Comparisons for JCA
Because JCA PICOs may differ from existing trial comparators, high-quality indirect treatment comparisons (ITCs) are often required.
Our specialists conduct:
- Bucher analyses
- Matching-adjusted indirect comparisons (MAICs) and other adjusted comparisons
- NMAs for complex evidence networks
- Scenario and sensitivity analyses linked to PICO variations
This ensures manufacturers have a defensible evidence base for EU-level assessment and national HTA follow-on.